If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
58
results.
Updated on
01/09/2024 [06:45:00]
Results 25 to 50 of 58
Absstract of: AU2023218995A1
The present disclosure is directed to methods of genetically subtyping peripheral t-cell lymphoma.
Absstract of: AU2023225810A1
Provided herein are compositions and methods related to depletion of diseased hematopoietic stem cells (HSC) using an anti-c-kit antibody. The compositions and methods described herein may be used to treat a subject in need of diseased HSC depletion due to a variety of diseases or disorders, such as myelodysplastic syndrome and acute myeloid leukemia.
Absstract of: AU2024205505A1
Abstract The present disclosure relates to the use of 1-4-bromo-5-1-ethyl-7-(methylamino)-2 oxo-1,2-dihydro-1,6-naphthyridin-3-yl-2-fluorophenyl-3-phenylurea or 1-(5-(7-amino-1 ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia-associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma.
Absstract of: WO2024173769A2
Described are 76 T-cells that express anon-signaling chimeric antigen receptor (CAR), wherein the CAR binds a tumor antigen such as CD19 or CD33. Also described are pharmaceutical compositions thereof and the method for the treatment of cancer such as leukemia.
Absstract of: EP4417205A1
The present invention relates to a composition for co-administration containing a 2,3,5-substituted thiophene compound. The composition has excellent inhibitory activity against cancer cells related to leukemia compared to treatment with the 2,3,5-substituted thiophene compound alone or an anticancer drug alone, and thus may be useful for the prevention, amelioration or treatment of leukemia.
Absstract of: EP4417616A1
The present invention relates to novel antagonists of the Liver X Receptors (LXRs) of formula (I) which can be used alone or in combination with other anti cancer therapies, such as the immune checkpoint blockers or cell adoptive cell therapy, preferably T cell adoptive cell therapy, to treat different cancers, including melanoma, Hodgkin lymphoma, renal, lung, bladder and head and neck cancers.Wherein:R<sub>1</sub> is OH or OSO<sub>3</sub>X;R<sub>2</sub> is OH or OSO<sub>3</sub>X;X at each occurrence is independently selected from H<sup>+</sup>, Na<sup>+</sup>, K<sup>+</sup> , NH<sub>4</sub><sup>+</sup> , pyridinium;and wherein when R<sub>1</sub> is OSO<sub>3</sub>X then R<sub>3</sub> is CH <sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, andwhen R<sub>1</sub> is OH then R<sub>3</sub> is an aryl or heteroaryl ring each of said aryl or heteroaryl ring being optionally substituted with one or more substituents independently selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub>haloalkoxy, C<sub>3-6</sub>cycloalkyl, OH, halogen, NH<sub>2</sub>, NH-C<sub>1-6</sub>alkyl, N(C<sub>1-6</sub>alkyl)2, NH-C(=O)C<sub>1-3</sub>alkyl
Absstract of: EP4417623A1
The present invention provides therapeutics for the treatment of CCR9-positive cancers such as T-cell acute lymphoblastic leukemia. In particular, the present invention provides a CCR9 targeting moiety. The present invention furthermore relates to a CCR9 targeting moiety comprising a further targeting moiety, preferably a CD1a targeting moiety.
Absstract of: EP4417201A1
The present invention relates to pharmaceutical compositions comprising chalcone compounds and in particular to pharmaceutical compositions comprising chalcone compounds of Formula A for use in the treatment of cancer. Embodiments of the invention have been particularly developed for use in the treatment of malignant pleural mesothelioma (MPM), renal cell carcinoma (RCC) or diffuse large B-cell lymphomas (DLBCL) and will be described hereinafter with reference to this application. The invention also relates to further uses of the chalcone compounds of Formula A.
Absstract of: US2024269178A1
The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Recept—or in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
Absstract of: WO2024168312A1
Aspects of the disclosure provide methods for treating a hematopoietic malignancy (e.g., acute myeloid leukemia). In some aspects, the disclosure provides methods of treatment using a population of genetically engineered CD33-deficient hematopoietic cells and gemtuzumab ozogamicin.
Absstract of: WO2024168062A1
The invention generally relates to the use of nuclear transport modulators, e.g., XPO1 inhibitors, for the treatment of cancer in a subject wherein the cancer is determined to have a wild type TP53 gene. The cancer can be any of the following cancer: endometrial cancer, ovarian cancer, kidney cancer, hepatocellular cancer, esophageal cancer, non-small cell lung cancer (NSCLC) adenocarcinoma, NSCLC squamous cell carcinoma, bladder cancer, pancreatic cancer, colorectal cancer, multiple myeloma, and glioblastoma. In a particular embodiment the use of the XPO1 inhibitor (or SINE compound - Selective Inhibitor of Nuclear Export) is for maintenance therapy in subject's diagnosed with endometrial cancer. The endometrial cancer can be advanced (Stage III or Stage IV) or recurrent endometrial cancer and the cancer has been determined to have a wild type TP53 gene.
Absstract of: US2024269224A1
The invention is directed to room temperature stable injectable formulations of carfilzomib or its pharmaceutically acceptable derivatives thereof in the form of ready to dilute solution and concentrates with no hemolytic potential. Further the invention is directed to a method for treating patients with relapsed or refractory multiple myeloma by administering such composition.
Absstract of: US2024269157A1
Methods for treating a cancer (such as, e.g., acute myeloid leukemia) comprising administering to a subject (such as, e.g., a subject who has acquired resistance to a therapy comprising at least one antineoplastic agent and/or at least one hypomethylating agent) at least one E-selectin antagonist, wherein the subject is further administered at least one antineoplastic agent (such as, e.g., venetoclax) and/or at least one hypomethylating agent are disclosed.
Absstract of: US2024271088A1
The present invention provides a method for maintaining and expanding a human primordial germ cell-like cell (hPGCLC) derived from a human primordial germ cell (hPGC) or a human pluripotent stem cell, including culturing hPGCLC in the presence of (i) a forskolin or phosphodiesterase 4 (PDE4) inhibitor, and (ii) one or more cytokines selected from the group consisting of a basic fibroblast growth factor (bFGF), a leukemia inhibitory factor (LIF), and an epidermal growth factor (EGF).
Absstract of: US2024269252A1
Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5-year survival rate of about 30%. Disclosed herein are composition and methods for treating leukemia with a biomaterial comprising a polymer scaffold, a dendritic cell activating factor, a dendritic cell recruitment factor, and at least one leukemia antigen. The biomaterial-based vaccine disclosed herein promotes a potent, durable and transferable immune response against acute myeloid leukemia to prevent cell engraftment and synergizes with chemotherapy to prevent relapse.
Absstract of: US2024269076A1
The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.
Absstract of: US2024270759A1
The present invention has disclosed SHP2 phosphatase inhibitors and its applications. Specifically, the present invention has disclosed the compounds shown in the general formula (I), methods of preparation thereof, and pharmaceutical compositions containing the compound, and their use as tyrosine phosphatase SHP-2 inhibitors in the treatment of leukemia, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, pancreatic cancer, head and neck squamous cell carcinoma, stomach cancer, liver cancer, anaplastic large cell lymphoma, and glioblastoma, wherein each substituent in general formula (I)k is as defined in the specification.
Absstract of: US2024270720A1
Disclosed herein are an indazole yl benzimidazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing, relieving or treating a protein kinase-related disease, including the derivative or the salt as an active ingredient, and the like. Further disclosed herein is a method for preventing or treating cancers, inflammatory diseases, or osteoporosis including administering the indazole yl benzimidazole derivative. The indazole yl benzimidazole derivative selectively inhibits Fms-like tyrosine kinase 3 (FLT3) when administered to a subject, and thus may be utilized for preventing, relieving or treating cancers including leukemia, inflammatory diseases including arthritis, or osteoporosis.
Absstract of: EP4414036A2
The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells. In other embodiments, the methods of the present invention relate to ex vivo purging of bone marrow or peripheral blood to remove cells that express one or more subunits of the interleukin-3 receptor such that the purged bone marrow or peripheral blood is suitable, e.g., for autologous stem cell transplantation to restore hematopoietic function.
Absstract of: WO2024163920A2
The present disclosure provides anti-CD180 binding molecules and uses thereof. In one embodiment, the anti-CD180 binding molecules are anti-CD180 antibodies. Also provided are anti-CD180 antibody-drug conjugates (ADCs) comprising a CD180-high expressing tumor-targeting monoclonal antibody or antigen-binding fragment thereof, a cytotoxic drug payload and a linker moiety conjugating the CD180-high expressing tumor-targeting antibody or the antigen-binding fragment thereof to the cytotoxic drug payload. The anti-CD180 antibodies or the antigen binding fragments thereof, and the ADCs comprising the anti-CD180 antibodies, or the antigen binding fragments thereof are useful in treating diseases, such as acute myeloid leukemia, mantle cell lymphoma, multiple myeloma. follicular lymphoma, B-acute lymphoblastic leukemia, or diffuse large B-cell lymphoma.
Absstract of: WO2024163764A2
Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Absstract of: WO2024161391A1
Nanoparticles comprising an outer surface covalently conjugated to 1,4-Bis(1,4,8,11-tetraazacyclotetradecan-l-yl)methylbenzene (AMD3100) or a derivative thereof capable of binding to C-X-C chemokine receptor type 4 (CXCR4) are provided. Methods for of treating a CXCR4 positive cancer, such as multiple myeloma or acute myeloid leukemia, in a subject in need thereof, methods of determining suitability for treatment and methods of covalently linking a molecule comprising a secondary amine to a lipid nanoparticle, are also provided.
Absstract of: AU2024204877A1
CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
Absstract of: US2024261246A1
The invention relates to the field of drugs, and particularly to use of a small molecule compound and lenalidomide in the preparation of a drug for treating multiple myeloma. How to promote the degradation of a transcription factor IKZF1 necessary for the proliferation of a downstream substrate, namely myeloma cells, is a difficulty in the treatment of multiple myeloma. According to the present invention, the combined use of the small molecule compound 2-BP and lenalidomide in the treatment of multiple myeloma obviously reduces the IKZF1 protein level, and the proliferation of the multiple myeloma cells is inhibited after the multiple myeloma cells are treated by the small molecule compound 2-BP in combination with lenalidomide.
Nº publicación: US2024261445A1 08/08/2024
Applicant:
WAHL RICHARD [US]
LONGTINE MARK [US]
SHIM KYU HWAN [US]
HOEGGER MARK [US]
WASHINGTON UNIV [US]
Wahl Richard,
Longtine Mark,
Shim Kyu-Hwan,
Hoegger Mark,
Washington University
Absstract of: US2024261445A1
The disclosure allows precision dosing of the therapeutic antibodies to individual patients based on their own, imaged, pharmacokinetics.
BOPI
Electronic site
